An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms MotHER
- Sponsors Genentech
- 30 May 2017 Planned End Date changed from 1 Dec 2022 to 31 Jan 2025.
- 30 May 2017 Planned primary completion date changed from 1 Dec 2022 to 31 Jan 2025.
- 04 Dec 2012 Planned end date changed from 1 Dec 2019 to 1 Dec 2022 as reported by ClinicalTrials.gov.